Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2022
Study RNLC3131 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in liver cirrhosis, defined by the presence of medically controlled ascites.
Epistemonikos ID: a29eb6c51989c2ee0231ce45dd9bdc583b9567ea
First added on: Oct 02, 2023